These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT. Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263 [TBL] [Abstract][Full Text] [Related]
3. Redesigning HVEM Interface for Selective Binding to LIGHT, BTLA, and CD160. Shrestha R; Garrett-Thomson SC; Liu W; Almo SC; Fiser A Structure; 2020 Nov; 28(11):1197-1205.e2. PubMed ID: 32795404 [TBL] [Abstract][Full Text] [Related]
4. A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator. Šedý JR; Balmert MO; Ware BC; Smith W; Nemčovičova I; Norris PS; Miller BR; Aivazian D; Ware CF J Biol Chem; 2017 Dec; 292(51):21060-21070. PubMed ID: 29061848 [TBL] [Abstract][Full Text] [Related]
5. HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160. Liu W; Chou TF; Garrett-Thomson SC; Seo GY; Fedorov E; Ramagopal UA; Bonanno JB; Wang Q; Kim K; Garforth SJ; Kakugawa K; Cheroutre H; Kronenberg M; Almo SC J Exp Med; 2021 Dec; 218(12):. PubMed ID: 34709351 [TBL] [Abstract][Full Text] [Related]
6. CD160 isoforms and regulation of CD4 and CD8 T-cell responses. El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432 [TBL] [Abstract][Full Text] [Related]
7. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Cai G; Freeman GJ Immunol Rev; 2009 May; 229(1):244-58. PubMed ID: 19426226 [TBL] [Abstract][Full Text] [Related]
8. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells. Šedý JR; Bjordahl RL; Bekiaris V; Macauley MG; Ware BC; Norris PS; Lurain NS; Benedict CA; Ware CF J Immunol; 2013 Jul; 191(2):828-36. PubMed ID: 23761635 [TBL] [Abstract][Full Text] [Related]
9. BTLA inhibition has a dominant role in the Battin C; Leitner J; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Olive D; Steinberger P Front Immunol; 2022; 13():956694. PubMed ID: 36081508 [TBL] [Abstract][Full Text] [Related]
10. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Cai G; Anumanthan A; Brown JA; Greenfield EA; Zhu B; Freeman GJ Nat Immunol; 2008 Feb; 9(2):176-85. PubMed ID: 18193050 [TBL] [Abstract][Full Text] [Related]
11. Herpes Simplex Virus 1 Latency and the Kinetics of Reactivation Are Regulated by a Complex Network of Interactions between the Herpesvirus Entry Mediator, Its Ligands (gD, BTLA, LIGHT, and CD160), and the Latency-Associated Transcript. Wang S; Ljubimov AV; Jin L; Pfeffer K; Kronenberg M; Ghiasi H J Virol; 2018 Dec; 92(24):. PubMed ID: 30282707 [TBL] [Abstract][Full Text] [Related]
12. T cell intrinsic heterodimeric complexes between HVEM and BTLA determine receptivity to the surrounding microenvironment. Cheung TC; Oborne LM; Steinberg MW; Macauley MG; Fukuyama S; Sanjo H; D'Souza C; Norris PS; Pfeffer K; Murphy KM; Kronenberg M; Spear PG; Ware CF J Immunol; 2009 Dec; 183(11):7286-96. PubMed ID: 19915044 [TBL] [Abstract][Full Text] [Related]
13. Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding. Spodzieja M; Kuncewicz K; Sieradzan A; Karczyńska A; Iwaszkiewicz J; Cesson V; Węgrzyn K; Zhukov I; Maszota-Zieleniak M; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963646 [TBL] [Abstract][Full Text] [Related]
14. HVEM, a cosignaling molecular switch, and its interactions with BTLA, CD160 and LIGHT. Rodriguez-Barbosa JI; Schneider P; Weigert A; Lee KM; Kim TJ; Perez-Simon JA; Del Rio ML Cell Mol Immunol; 2019 Jul; 16(7):679-682. PubMed ID: 31160757 [No Abstract] [Full Text] [Related]
15. Increased Heterologous Protein Expression in Drosophila S2 Cells for Massive Production of Immune Ligands/Receptors and Structural Analysis of Human HVEM. Liu W; Vigdorovich V; Zhan C; Patskovsky Y; Bonanno JB; Nathenson SG; Almo SC Mol Biotechnol; 2015 Oct; 57(10):914-22. PubMed ID: 26202493 [TBL] [Abstract][Full Text] [Related]
16. Structure of human cytomegalovirus UL144, an HVEM orthologue, bound to the B and T cell lymphocyte attenuator. Bitra A; Nemčovičová I; Picarda G; Doukov T; Wang J; Benedict CA; Zajonc DM J Biol Chem; 2019 Jul; 294(27):10519-10529. PubMed ID: 31126984 [TBL] [Abstract][Full Text] [Related]
17. The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Steinberg MW; Cheung TC; Ware CF Immunol Rev; 2011 Nov; 244(1):169-87. PubMed ID: 22017438 [TBL] [Abstract][Full Text] [Related]
18. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier. Del Rio ML; Bravo Moral AM; Fernandez-Renedo C; Buhler L; Perez-Simon JA; Chaloin O; Alvarez Nogal R; Fernandez-Caso M; Rodriguez-Barbosa JI Transl Res; 2017 Mar; 181():83-95.e3. PubMed ID: 27702550 [TBL] [Abstract][Full Text] [Related]
19. HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage. Muscate F; Stetter N; Schramm C; Schulze Zur Wiesch J; Bosurgi L; Jacobs T Front Immunol; 2018; 9():2611. PubMed ID: 30483269 [TBL] [Abstract][Full Text] [Related]